Intravitreal Bevacizumab for Inflammatory Neovascular Membranes

Sponsor

Asociación para Evitar la Ceguera en México (Other)

Overall Status

Completed

CT.gov ID

NCT00407121

Collaborator

(none)

Location

Duration (Months)

Study Details

Study Description

Brief Summary

Intravitreal injection of Bevacizumab in patients with Neovascular Membranes secondary to intraocular inflammation. We injected a single injection of Bevacizumab (2.5 mg/0.1 ml) and evaluate visual acuity , Fluorescein angiogram and retinal thickness by Optical Coherence Tomography (OCT) in 4 patients with Vogt Koyanagi Harada disease, 1 patient with Serpiginous Choroidopathy and 1 patient with Multifocal Choroiditis.

Condition or Disease	Intervention/Treatment	Phase
Vogt Koyanagi Harada Disease Serpiginous Choroiditis Multifocal Choroiditis	Drug: Bevacizumab Procedure: Intravitreal Injection of Bevacizumab	Phase 3

Study Design

Study Type:

Interventional

Allocation:

Non-Randomized

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Intravitreal Bevacizumab for the Treatment of Neovascular Membranes in Patients With Intraocular Inflammation

Study Start Date :

Aug 1, 2006

Study Completion Date :

Nov 1, 2006

Outcome Measures

Primary Outcome Measures

Best corrected visual acuity []
Retinal thickness by OCT []
Leakage in Fluorescein angiogram []

Eligibility Criteria

Criteria

Ages Eligible for Study:

25 Years to 60 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Clinical Diagnose
Patient Consent
Chronic stage of inflammation

Exclusion Criteria:

only eye
age lower than 30 yo.
Systemic condition

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Asociacion para Evitar la Ceguera en Mexico	Mexico	Distrito Federal	Mexico	04030

Sponsors and Collaborators

Asociación para Evitar la Ceguera en México

Investigators

Principal Investigator: Veronica Kon-Jara, MD, Asociación para Evitar la Ceguera en México
Study Chair: LuzElena Concha-Del Rio, MD, Asociación para Evitar la Ceguera en México